Return to homepagePandemic Pact

Advanced Development of Vaccines for Filoviruses

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 75N93020C00040-P00010-9999-1

Grant search

Key facts

  • Disease

    Lassa Haemorrhagic Fever, Ebola, Marburg virus disease

  • Start & end year

    2020
    2026

  • Known Financial Commitments (USD)

    $1,033,940

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    JOHN ELDRIDGE

  • Research Location

    United States of America

  • Lead Research Institution

    AURO VACCINES LLC

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

To support the advanced development of multivalent vaccine candidates for filoviruses and Lassa Fever. This contract aims to formulate a multivalent vaccine that provides protection against several pathogens, including Ebola virus, Marburg virus and Lassa Fever. It may support cGMP manufacture of a stable lyophilized vaccine formulation and preparation and submission of an IND to support eventual clinical evaluation.